12,372 trials
Epilepsy · Partial Onset Seizures
Primary: Percentage of Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group Who Are Seizure Free for 26 Consecutive Weeks of Treatment During the Evaluation…
Hepatitis C, Chronic
Primary: Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Completion of All Study Therapy (SVR24) — 92.0; 96.2 percentage of participants — p=<0.001
Urinary Tract Infection
Primary: Incidence of Adverse Drug Reactions During 7-day Treatment of uUTI Symptoms With Canephron® N — 0 Adverse Drug Reactions
Fatigue · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Prorated AUC of Total Fatigue as Measured by the Brief Fatigue Inventory (BFI) at Baseline and at Weeks 1-4 — 50.33; 47.15 units on a scale — p=0.317
Non-24-Hour Sleep-Wake Disorder
Primary: Maintenance of Entrainment (aMT6s) in Subjects With N24HSWD. — 9; 2 participants
Mild Cognitive Impairment
Primary: Change in Cognitive Scores: Alzheimer Disease Assessment Scale-cognitive. Subscale (ADAS-cog) — -4.23; -4.31 units on a scale
HIV · Hyperlipidemia · Hypertriglyceridemia
Primary: Change From Baseline Triglycerides — 125 units on a scale
Lymphocytic Leukemia, Chronic
Primary: Progression-free Survival (PFS) — 15.7; 28.9 months — p=<0.0001
Diabetes Mellitus, Type 2
Primary: Change From Baseline up to 24 Weeks in Hemoglobin A1c (HbA1c) — -1.286; -1.338 percentage of glycosylated hemoglobin — p=0.403
Treatment Outcome
Primary: Change From Baseline in the Changes in Sexual Functioning Questionnaire Short-Form (CSFQ-14) Total Score at Week 8 — 8.8; 6.6 scores on a scale — p=0.013
Graft Versus Host Disease · Recurrent Adult Acute Lymphoblastic Leukemia
Primary: Mean Cumulative Prednisone Dose (mg/kg) Over 42 Days From the Start of Treatment — 22.2; 27.1; 38.4; 41.3 milligrams per kilogram — p=0.08
Type 2 Diabetes
Primary: Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c) — -1.42; -1.36 percentage of glycosylated hemoglobin — p=<0.001
Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 93.2; 27.3; 85.2 percentage of participants
Hepatitis C, Chronic
Primary: Percentage of Participants Achieving Sustained Virologic Response (SVR)24 — 61.9 percentage of participants
Diabetes Mellitus, Type 1
Primary: Change From Baseline up to 24 Weeks in Hemoglobin A1c (HbA1c) — -0.352; -0.460 percentage of glycosylated hemoglobin — p=0.055